MannKind Corporation (NASDAQ:MNKD) the developer of the inhaled insulin Afrezza, suffered a minor drop in its shares as the FDA delayed the drug’s approval. MannKind Corporation (NASDAQ:MNKD) shares after opening at $6.12 moved to $6.44 on last trade day and at the end of the day closed at $6.32. Company price to cash ratio as 33.67. MannKind Corporation (NASDAQ:MNKD) showed a positive weekly performance of 57.21%.
eBay Inc. (NASDAQ:EBAY) just added a new category under “Coins & Paper Money” that now allows sales of “Virtual Currency.” eBay Inc. (NASDAQ:EBAY) shares fell -1.94% in last trading session and ended the day on $52.95. EBAY return on equity ratio is recorded as 12.80% and its return on assets is 7.20%. eBay Inc. (NASDAQ:EBAY) yearly performance is -5.23%.
Gilead Sciences Inc. (NASDAQ:GILD) should hear within six months whether regulators approve a drug combination that can be taken orally to defeat hepatitis C. Gilead Sciences, Inc. (NASDAQ:GILD) shares moved up 0.04% in last trading session and was closed at $72.23, while trading in range of $70.72 – $73.73. Gilead Sciences, Inc. (NASDAQ:GILD) year to date (YTD) performance is -3.82%.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) on 2 April announced the appointment of Hugh M. Cole to the position of senior vice president and chief business officer. Mr. Cole will be responsible for global business and corporate development, licensing and strategic planning. He will report to ARIAD’s chairman and chief executive officer, Harvey J. Berger, M.D. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is -10.17%. On last trading day company shares ended up $7.24. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average (SMA50) is -10.55%. Analysts mean target price for the company is $9.06.
Leave a Reply